quinazolines has been researched along with Adenoma, Prostatic in 206 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (3.40) | 18.7374 |
| 1990's | 59 (28.64) | 18.2507 |
| 2000's | 96 (46.60) | 29.6817 |
| 2010's | 41 (19.90) | 24.3611 |
| 2020's | 3 (1.46) | 2.80 |
| Authors | Studies |
|---|---|
| Bernikov, AN; Loran, OB; Pushkar, DY | 1 |
| Hori, Y; Ohyama, K; Sugiura, M | 1 |
| Ergakov, DV; Martov, AG | 1 |
| Cong, BN; Duy, TN; Hoang, NN; Ivkin, DY; Krasnova, MV; Minh, TD; PhamTien, D; Povydysh, MN; Quoc, BP; Thai, HP; Thanh Ha, TN; Thi Lan, PD; Thi, HN | 1 |
| Dogan, M; Halat, AO; Karalar, M; Keles, I; Kutluksaman, B | 1 |
| Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B | 1 |
| Belal, F; Borg, H; Fathy, M; Walash, MI; Zayed, S | 1 |
| Al-Jarrah, M; Al-Omari, MH; Aljarrah, Q; Alzoubi, A; Elheis, M; Jamal, A | 1 |
| Miernik, A; Praus, F | 1 |
| Kaplan, SA | 1 |
| Chung, JH; Han, JH; Jo, JK; Kang, DH; Kim, TH; Lee, JW; Lee, JY; Lee, KS; Lee, SH; Lee, SW | 1 |
| Carrillo-Ruiz, JD; González-Valle, JC; Guzman-Esquivel, J; Labra-Salgado, IR; Maldonado-Ávila, M; Manzanilla-García, HA; Rosas-Nava, E; Sierra-Ramírez, JA | 1 |
| Campbell, JR; Chang, DF; Colin, J; Schweitzer, C | 1 |
| Hassoun, G; Kedem, E; Nassar, L; Shahar, E | 1 |
| Kara, O; Yazici, M | 1 |
| Aktas, BK; Baykam, MM; Bulut, S; Deren, T; Gokkaya, CS; Memis, A; Ozden, C; Tagci, S | 1 |
| Elsheikh, MG; Salah Azab, S | 1 |
| Altay, AB; Apaydin, E; Bademkiran, F; Cikili, N; Semerci, MB; Turna, B; Umul, M | 1 |
| Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT | 2 |
| Feng, ZJ; Zhou, Q; Zhu, LL | 1 |
| Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
| Adbi, H; Ben Raies, N; Ben Rhouma, S; Binous, MY; H'sairi, M; Horchani, A; Mosbah, AT; Nouira, Y | 1 |
| Dixon, S; Fraser, LA; Hayward, J; Hwang, YJ; McArthur, E; Ordon, M; Welk, B | 1 |
| Armarnik, S; Assia, EI; Mimouni, M; Rosen, E; Segev, F | 1 |
| Adamo, EB; Altavilla, D; Crea, G; Irrera, N; Lorenzini, C; Marini, H; Micali, A; Minutoli, L; Pisani, A; Puzzolo, D; Rinaldi, M; Squadrito, F; Valenti, A | 1 |
| Ciotkowska, A; Gratzke, C; Hennenberg, M; Herlemann, A; Janich, S; Liu, C; Rutz, B; Stief, CG; Strittmatter, F; Tamalunas, A; Waidelich, R; Wang, Y | 1 |
| Arikan, G; Bozkurt, O; Demir, O; Durak, I; Esen, A; Saatci, AO; Yaman, A | 1 |
| Mamalis, N | 1 |
| Bar-Yosef, Y; Kaver, I; Laufer, M; Mabjeesh, NJ; Matzkin, H; Neulander, EZ | 1 |
| Roehrborn, CG; Rosen, RC | 1 |
| Babayan, RK; Wiygul, J | 1 |
| Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T | 1 |
| Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY | 1 |
| Cheon, J; Chung, BH; Chung, MK; Kim, MK; Kim, SW; Lee, JY; Lee, KS; Lee, SW; Park, JK; Park, K | 1 |
| Akarasakul, D; Choeypunt, N; Chotikawanich, E; Kongwiwatanakul, S; Leungwattanakij, S; Lojanapiwat, B; Noppakulsatit, P; Permpongkosol, S; Petchpaibuol, T; Pripatnanont, C; Tantiwong, A; Tongbai, T; Wanamkang, T; Watanachote, D | 1 |
| Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA | 1 |
| Chung, BH; Lee, SH; Mah, SY; Park, KK | 1 |
| Choo, MS; Han, JY; Lee, HN; Lee, KS; Lee, YS | 1 |
| Cho, JS; Choo, MS; Han, JY; Kim, JC; Lee, KS; Lee, YS; Song, K | 1 |
| Alan, C; Eren, AE; Ersay, AR; Ertung, Y; Kırılmaz, B; Koçoğlu, H | 1 |
| Güner, E; Güner, S; Mutlu, B; Taşçi, AI | 1 |
| Atahan, Ö; Budak, YU; Karadağ, E; Öner, S | 1 |
| Evangelou, AM; Giannakopoulos, XK; Giotis, C; Karkabounas, SCh; Peschos, D; Simos, YV; Verginadis, II | 1 |
| Krilad-O-Larn, S; Permpongkosol, S; Ratana-O-Larn, K | 1 |
| Akyüz, M; Güneş, M; Kalkan, S; Karaman, MI; Koca, O; Öztürk, Mİ | 1 |
| Hill, TM; McEwen, C; Sherman, JJ; Welch, RW | 1 |
| Achtsidis, V; Fountas, KN; Komninos, C; Tentolouris, N; Theodoropoulou, S; Theodossiadis, PG | 1 |
| Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD | 1 |
| Lee, HJ; Lee, JW | 1 |
| Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J | 1 |
| Ahtoy, P; Chrétien, P; Delfolie, A; Dupain, T; Rauch, C; Rouchouse, A | 1 |
| Kirby, RS; Pool, JL | 1 |
| Atan, A; Başar, MM; Ozergin, O; Yildiz, M | 1 |
| Anglin, IE; Glassman, DT; Kyprianou, N | 1 |
| Doherty, AP | 1 |
| Larson, TR | 1 |
| Barras, M; Palea, S | 1 |
| Bressolle, F; Costa, P; Delmas, V; Mottet, N; Robert, M | 1 |
| Armstrong, P; Borer, J | 1 |
| De Nunzio, C; Franco, G; Iori, F; Laurenti, C; Leonardo, C; Minardi, V | 1 |
| Nordling, J; Roehrborn, CG; Van Kerrebroeck, P | 1 |
| Lee, M | 1 |
| O'Leary, MP | 2 |
| Romics, I | 1 |
| Lowe, FC; Weiner, DM | 1 |
| Forrest, J; Gittelman, M; Jacobs, S; Kim, D; Marks, LS; Roehrborn, CG | 1 |
| Wyllie, MG | 1 |
| Kyprianou, N; Tahmatzopoulos, A | 1 |
| Brown, GA; Sussman, DO | 1 |
| de Reijke, TM; Klarskov, P | 1 |
| Simon, HB | 1 |
| Byrne, DJ; McNeill, AS; Rizvi, S | 1 |
| Guay, DR | 1 |
| Lowe, FC | 1 |
| Hargreave, TB; McNeill, SA; Roehrborn, CG | 1 |
| Akbay, E; Bozlu, M; Cayan, S; Görür, S; Ulusoy, E | 1 |
| Nordling, J | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J | 1 |
| Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A | 1 |
| Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L | 1 |
| MacDonald, R; Wilt, TJ | 1 |
| Roehrborn, CG | 4 |
| Egilmez, T; Guvel, S; Kilinc, F; Ozkardes, H; Pourbagher, MA; Turunc, T | 1 |
| McVary, KT | 1 |
| Irani, J | 1 |
| Armitage, JN; Emberton, M | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ | 2 |
| Kuritzky, L; Rosenberg, MT; Sadovsky, R | 1 |
| Fitt, AW; Settas, G | 1 |
| Fitzpatrick, JM | 1 |
| Emberton, M | 1 |
| de la Rosette, JJ; Michel, MC; van Dijk, MM | 1 |
| De La Taille, A; Desgrandchamps, F; Doublet, JD | 1 |
| Elhilali, MM | 1 |
| Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G | 1 |
| Kwok, C; Tay, YK; Wang, YS | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G | 1 |
| Fujita, Y; Inamura, M; Koyama, T; Miyoshi, T; Ohashi, Y; Ohki, K; Okamoto, S; Oshika, T; Sakabe, I; Takahashi, K; Yasuma, T | 1 |
| Resnick, MI; Roehrborn, CG | 1 |
| Gonzalez, RR; Kaplan, SA; Te, AE | 1 |
| Sciarra, A | 1 |
| Adibelli, FM; Akova, YA; Altan-Yaycioglu, R; Gul, U; Pelit, A; Yaycioglu, O | 1 |
| Awan, MA; Cheung, CM; Peh, KK; Sandramouli, S | 1 |
| Brown, DJ; Mariappan, P; McNeill, AS | 1 |
| Blouin, J; Blouin, MC; Dragomir, A; Lapointe, A; Perreault, S | 1 |
| Byrne, DJ; Goodman, CM; Gopi, SS; Robertson, A | 1 |
| Chang, R; Chang, YW; Dong, SH; Kim, BH; Kim, HJ; Kim, SY; Kim, YW | 1 |
| Gupta, B; Gupta, VK; Singh, AK | 1 |
| Adayener, C; Akyol, I; Ates, F; Iseri, C; Senkul, T; Yilmaz, O | 1 |
| Andersson, KE; Ek, A; Hedlund, H | 1 |
| Lepor, H; Shapiro, E | 1 |
| Blondin, P; Buzelin, JM; Hebert, M | 1 |
| Jardin, A | 2 |
| Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S | 1 |
| Mensink, HJ | 1 |
| Ferretti, S; Larosa, M; Salsi, P; Simonazzi, M | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A | 1 |
| Gentili, G; Mautone, A; Milani, M; Tucci, G | 1 |
| Antonelli, D; Belloni, M; Bernasconi, S; Buizza, C; Chisena, S; Mandressi, A; Zaroli, A | 1 |
| De Sy, W; Santoni, JP; Schulman, CC; Tomas, M; Vandendris, M | 1 |
| Brasso, K; Flyger, H; Hald, T; Hansen, BJ; Meyhoff, HH; Mortensen, S; Nordling, J; Schou, J; Thorup Andersen, J; Walter, S | 1 |
| Ishida, Y; Kawabe, K; Kurimoto, S; Moriyama, N; Nakamura, T; Orikasa, E | 1 |
| Fitton, A; McTavish, D; Wilde, MI | 1 |
| Casadei, G; Martelli, A; Pacifico, P | 1 |
| Grange, JC; Lukacs, B; McCarthy, C | 1 |
| Hansen, BJ | 1 |
| Portet-Brunet, L | 1 |
| Flyger, H; Hansen, BJ; Mensink, HJ; Meyhoff, HH; Mortensen, S | 1 |
| Blondin, P; Du Boys, B; Grippon, P; Lassale, C; Lukacs, B; MacCarthy, C | 1 |
| Jardin, A; Leplège, A; Lukacs, B; Thibault, P | 1 |
| Hansen, BJ; Larsen, EH; Mensink, HJ; Meyhoff, HH; Mogensen, P; Nordling, J | 1 |
| Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S | 1 |
| Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP | 1 |
| Lukacs, B | 1 |
| Casadei, G; Colombo, R; Di Silverio, F; Giberti, C; Martorana, G; Pacifico, P; Rigatti, P; von Heland, M | 1 |
| Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
| Buzelin, JM; Fonteyne, E; Khan, A; Kontturi, M; Witjes, WP | 1 |
| Comet, D; Grange, JC; Lukacs, B; Thibault, P | 1 |
| Flyger, H; Hald, T; Hansen, BJ; Hendolin, N; Mensink, HJ; Mortensen, S; Nordling, J; Riehmann, M | 1 |
| de la Rosette, JJ; Debruyne, FM; Geffriaud, C; Vignoli, GC; Wijkstra, H; Witjes, WP; Zerbib, M | 1 |
| Matushevskiĭ, IA; Mazo, EB; Nikitin, IuIu | 1 |
| Kirby, RS | 1 |
| Comet, D; Grange, JC; Lukacs, B; McCarthy, C | 2 |
| Chapple, CR | 2 |
| Suzuki, H | 1 |
| Angel, I; Buzelin, JM; Delauche Cavallier, MC; Martin, D | 1 |
| Cologna, A; Kaplan, SA; Kohn, IJ; Martins, AC; Reis, RB; Suaid, HJ; Te, AE | 1 |
| Colloi, D; Debruyne, FM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Jardin, A; McCarthy, C; Resel, L; Witjes, WP | 1 |
| Borras-Blasco, J; Navarro-Ruiz, A; Vela-Casasempere, P | 1 |
| Bèïque, L; Evans, MF; Por, CP | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A | 3 |
| Djavan, B; Marberger, M | 1 |
| Comet, D; Grange, JC; Lukacs, B; Mc Carthy, C | 1 |
| Claes, H; De Reijke, TM; Folkestad, B; Höfner, K; Speakman, MJ | 1 |
| Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG | 1 |
| Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P | 1 |
| Comet, D; Grange, JC; Lukacs, B | 1 |
| Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M | 1 |
| Ausín, I; Barajas, R; Gabriel, R; Vela Navarrete, R | 1 |
| Fourcade, RO | 1 |
| Clifford, GM; Farmer, RD | 1 |
| Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M | 1 |
| Geffriaud-Ricouard, C; Hargreave, TB; McNeill, SA; Roehrborn, CG; Santoni, J | 1 |
| McNeill, SA | 1 |
| Van Kerrebroeck, PE | 1 |
| De la Rosette, JJ; Farmer, RD; Herings, RM; Leufkens, HG; Man in 't Veld, AJ; Souverein, PC | 1 |
| Clementi, G; Costantino, G; Matera, M | 1 |
| Altenbach, RJ; Bai, H; Basha, FZ; Brune, ME; Buckner, SA; Carroll, WA; Drizin, I; Hancock, AA; Kerwin, JF; Lebold, SA; Lee, E; Meyer, MD; Pratt, JK; Sippy, KB; Tietje, K; Wendt, MD | 1 |
| Dutkiewics, S | 1 |
| Flannery, MT; Michel, MC; Narayan, P | 1 |
| Chess-Williams, R | 1 |
| McKeage, K; Plosker, GL | 1 |
| de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS | 1 |
| Jardin, A; Laval, KU; van Cangh, P; van Kerrebroec, P | 1 |
| Höfner, K; Jonas, U | 1 |
| Chern, JW; Choong, CM; Chueh, SC; Guh, JH; Teng, CM | 1 |
| Hansen, BJ; Meyhoff, HH | 1 |
| Kondo, S; Morita, T | 1 |
| Asano, H; Fujita, T; Hirabayashi, S; Kato, N; Kinukawa, T; Ohshima, S; Ono, Y | 1 |
| Attali, P; Delauche-Cavallier, MC; Teillac, P | 1 |
| Kaneko, S; Koyanagi, T; Kumamoto, Y; Maru, A; Nishizawa, O; Orikasa, S; Togashi, M; Tsuchida, S; Tsukamoto, T; Yachiku, S | 1 |
| Kato, Y; Kawabe, K; Kimura, R; Maruyama, M; Matsuoka, Y; Suzuki, M; Yamada, S | 1 |
| Kobayashi, S | 1 |
| Bauer, P; Carbin, BE; Friskand, M; Moyse, D | 1 |
| Ramsay, JW; Scott, GI; Whitfield, HN | 1 |
| Kondo, A; Mitsuya, H; Otani, T; Takita, T | 1 |
| Aso, Y; Ishibashi, A; Koshiba, K; Kumamoto, Y; Nishizawa, O; Ogawa, A; Tomita, Y; Tsuchida, S; Tsukamoto, T; Yokoyama, E | 1 |
| Aoyama, T; Furuya, S; Honma, A; Kumamoto, Y; Miyamoto, S; Takagi, Y; Takatsuka, K; Tamiya, T; Tsukamoto, T; Yokoyama, E | 1 |
42 review(s) available for quinazolines and Adenoma, Prostatic
| Article | Year |
|---|---|
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urological Agents | 2017 |
[LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Tamsulosin; Treatment Outcome; Urological Agents | 2019 |
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Topics: Apoptosis; Dutasteride; Endocrine System; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urological Agents | 2016 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2008 |
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome | 2008 |
Watchful waiting in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Transurethral Resection of Prostate | 2009 |
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2013 |
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood-Brain Barrier; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha-1 | 2001 |
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component.
Topics: Adrenergic Antagonists; Apoptosis; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Signal Transduction; Tumor Cells, Cultured | 2002 |
Current treatment options for benign prostatic hyperplasia and their impact on sexual function.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Erectile Dysfunction; Finasteride; Humans; Laser Coagulation; Male; Middle Aged; Minimally Invasive Surgical Procedures; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Behavior; Transurethral Resection of Prostate | 2003 |
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines | 2003 |
Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Animals; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Quinazolines; Rabbits; Severity of Illness Index; Transurethral Resection of Prostate; Urethral Obstruction; Urinary Retention | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2003 |
Alfuzosin for the management of benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Male; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quinazolines | 2003 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines | 2004 |
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Tract; Urologic Diseases | 2004 |
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urination Disorders | 2005 |
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Time Factors | 2006 |
Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
The natural history of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Disease Progression; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination | 2006 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation; Erectile Dysfunction; Humans; Libido; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2006 |
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sexual Dysfunction, Physiological; Urodynamics; Urologic Diseases | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
Clinical results with alpha-blockers in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Humans; Male; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Urodynamics | 1994 |
Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1993 |
Using a large clinical database to assess the effectiveness of alfuzosin.
Topics: Adrenergic alpha-Antagonists; Aged; Cost-Benefit Analysis; Databases, Factual; Decision Making, Computer-Assisted; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Surveys and Questionnaires; Treatment Outcome | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Delayed-Action Preparations; Humans; Hypotension, Orthostatic; Male; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction | 1998 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient Selection; Plant Extracts; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Female; Humans; Hypertension; Male; Multicenter Studies as Topic; Prazosin; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic | 1998 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizziness; Dose-Response Relationship, Drug; Doxazosin; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urologic Diseases | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination; Urine | 2001 |
Does acute urinary retention respond to alpha-blockers alone?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention | 2001 |
Worldwide experience with alfuzosin and tamsulosin.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Controlled Clinical Trials as Topic; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urodynamics | 2001 |
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urethral Obstruction | 2001 |
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urologic Diseases | 2002 |
Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
Topics: Absorption; Adrenergic alpha-Antagonists; Aged; Area Under Curve; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Tissue Distribution | 2002 |
Alfuzosin: a clinically uroselective alpha1-blocker.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; Urination Disorders | 2002 |
78 trial(s) available for quinazolines and Adenoma, Prostatic
| Article | Year |
|---|---|
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Choroid; Color Vision; Diagnostic Techniques, Ophthalmological; Humans; Iris; Male; Middle Aged; Night Vision; Organ Size; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Tamsulosin; Tomography, Optical Coherence | 2017 |
Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urodynamics | 2013 |
A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Device Removal; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Recovery of Function; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2014 |
Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Sectional Studies; Double-Blind Method; Humans; Intraoperative Complications; Iris Diseases; Lens Implantation, Intraocular; Male; Phacoemulsification; Prolapse; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Risk Factors; Severity of Illness Index; Sulfonamides; Tamsulosin; Video Recording | 2014 |
Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dizziness; Drug Therapy, Combination; Headache; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Retention | 2014 |
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urological Agents | 2015 |
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Urinary Catheterization; Urinary Retention | 2009 |
An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quinazolines; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2010 |
Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Erectile Dysfunction; Humans; Male; Middle Aged; Nocturia; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Thailand | 2010 |
Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Goals; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction | 2011 |
The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Muscle Contraction; Prospective Studies; Prostatic Hyperplasia; Prostatism; Quinazolines; Time Factors; Urinary Bladder Neck Obstruction | 2011 |
Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Severity of Illness Index; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Treatment Outcome | 2011 |
Effects of pulsed electromagnetic fields on benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Electromagnetic Fields; Humans; Male; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatism; Pulsed Radiofrequency Treatment; Quinazolines; Severity of Illness Index | 2011 |
Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Thailand; Urination; Urologic Diseases | 2011 |
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Urination Disorders | 2012 |
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Area Under Curve; Biological Availability; Cross-Over Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 2002 |
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Biological Availability; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Preoperative Care; Probability; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Transurethral Resection of Prostate; Treatment Outcome | 2003 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2003 |
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Drug Administration Schedule; Humans; Hypotension; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Safety; Treatment Outcome; Urodynamics | 2003 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Prostate size influences the outcome after presenting with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Prostate; Prostatic Hyperplasia; Quinazolines; Treatment Failure; Urinary Retention | 2004 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Emergencies; Humans; Life Tables; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Recurrence; Urinary Catheterization; Urinary Retention | 2005 |
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Single-Blind Method; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders | 2005 |
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Organ Size; Probability; Prostatic Hyperplasia; Quinazolines; Statistics, Nonparametric; Treatment Failure; Urinary Retention | 2006 |
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Risk Factors; Treatment Outcome; Urinary Retention | 2006 |
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Pain; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urologic Diseases | 2006 |
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Hyperplasia; Quinazolines; Urination | 2007 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Treatment Outcome; Urination Disorders | 2007 |
The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Intraoperative Complications; Iris Diseases; Male; Middle Aged; Phacoemulsification; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Single-Blind Method; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Visual Acuity | 2007 |
A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Topics: Adrenergic alpha-Antagonists; Aged; Catheterization; Community Health Services; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Effects of prazosin in patients with benign prostatic obstruction.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha; Urodynamics | 1983 |
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination; Urination Disorders | 1993 |
[Alfuzosin in the treatment of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urodynamics | 1993 |
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urodynamics | 1994 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Follow-Up Studies; Heart Rate; Humans; Long-Term Care; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination; Urodynamics | 1994 |
[Assessment of the effects of alfuzosin on miction with dynamic echography].
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Ultrasonography; Urinary Bladder Neck Obstruction; Urination | 1994 |
Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
Topics: Activities of Daily Living; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Humans; Italy; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urination; Vasodilation | 1995 |
Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cross-Over Studies; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 1994 |
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Urination Disorders | 1995 |
Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Surveys and Questionnaires; Time Factors; Urodynamics | 1993 |
Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Surveys and Questionnaires; Time Factors | 1993 |
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urinary Bladder Neck Obstruction; Urination Disorders; Urodynamics | 1996 |
Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Evaluation; Follow-Up Studies; France; Humans; Male; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Risk Factors; Safety | 1996 |
Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Family Practice; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexuality; Surveys and Questionnaires; Time Factors; Treatment Failure | 1996 |
Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Denmark; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Netherlands; Placebos; Prostatic Hyperplasia; Quinazolines; Time Factors | 1996 |
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Posture; Prostatic Hyperplasia; Quinazolines; Safety; Treatment Outcome; Urodynamics | 1997 |
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention; Urination | 1997 |
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Rheology; Single-Blind Method; Urinary Bladder Neck Obstruction; Urination; Urodynamics | 1997 |
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urination | 1997 |
Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Hyperthermia, Induced; Male; Microwaves; Prostatic Hyperplasia; Quality of Life; Quinazolines; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome; Urination Disorders | 1998 |
Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Safety; Sexuality | 1998 |
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urination Disorders; Urodynamics | 1998 |
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 1998 |
Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Double-Blind Method; Humans; Hypotension; Male; Middle Aged; Placebos; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urination Disorders; Urodynamics | 1993 |
[Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Follow-Up Studies; France; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Behavior; Surveys and Questionnaires | 1999 |
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Ejaculation; Erectile Dysfunction; Humans; Incidence; Libido; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Treatment Outcome; Urethral Obstruction | 1999 |
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 1999 |
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia; Quinazolines; Time Factors; Urinary Retention | 2000 |
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Safety; Urination Disorders | 2000 |
Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Delayed-Action Preparations; Evaluation Studies as Topic; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Prostatic Hyperplasia; Quality of Life; Quinazolines; Spain; Treatment Outcome; Urination Disorders | 2000 |
Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Time Factors | 2000 |
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Double-Blind Method; Humans; Male; Prazosin; Prostatic Hyperplasia; Quality of Life; Quinazolines; Severity of Illness Index | 2000 |
The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urination Disorders | 2000 |
The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors | 2001 |
[Long-term therapy of benign prostatic hyperplasia. Our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Mepartricin; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Time Factors | 2001 |
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Canada; Double-Blind Method; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; United States; Urination; Urination Disorders | 2001 |
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Follow-Up Studies; Humans; Male; Middle Aged; Probability; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Treatment Outcome | 2002 |
[The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urination | 1992 |
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors; Urination; Urination Disorders; Urodynamics | 1992 |
[A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Alanine; Chi-Square Distribution; Double-Blind Method; Drug Combinations; Glutamates; Glycine; Humans; Japan; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urination; Urination Disorders | 1990 |
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Time Factors; Urinary Retention; Urination | 1991 |
Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 1991 |
A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction; Urodynamics | 1985 |
[Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction].
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Diseases; Prostatic Hyperplasia; Quinazolines; Urinary Bladder, Neurogenic; Urination; Urination Disorders | 1987 |
[A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sympathetic Nervous System; Urination; Urination Disorders | 1987 |
[Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androgen Antagonists; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nandrolone; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction; Urination | 1987 |
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Europe; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Random Allocation; Urination Disorders | 1988 |
86 other study(ies) available for quinazolines and Adenoma, Prostatic
| Article | Year |
|---|---|
[The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
Topics: Adrenergic alpha-Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome | 2022 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Syncope; Tamsulosin | 2019 |
[The use of alfuzosin in the treatment of patients with acute urinary retention].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Transurethral Resection of Prostate; Urinary Retention | 2020 |
Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate.
Topics: 5-alpha Reductase Inhibitors; Animals; Dutasteride; Male; Medicine, East Asian Traditional; Prostatic Hyperplasia; Quinazolines; Random Allocation; Rats; Rats, Wistar; Testosterone Propionate; Urination; Urological Agents; Vietnam | 2021 |
Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chromatography, High Pressure Liquid; Drug Compounding; Humans; Male; Prostatic Hyperplasia; Quinazolines; Reference Standards; Reproducibility of Results; Spectrometry, Fluorescence; Tamsulosin; Vardenafil Dihydrochloride; Vasodilator Agents | 2019 |
Successful reversal of isolated delayed spinal cord ischemia following endovascular abdominal aneurysm repair.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiography, Digital Subtraction; Aortic Aneurysm, Abdominal; Aortography; Arterial Pressure; Blood Vessel Prosthesis Implantation; Computed Tomography Angiography; Endovascular Procedures; Fecal Incontinence; Humans; Magnetic Resonance Imaging; Male; Prostatic Hyperplasia; Quinazolines; Spinal Cord Ischemia; Time Factors; Treatment Outcome | 2019 |
Re: Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Quinazolines; Sulfones; Urination Disorders | 2013 |
Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cerebrospinal Fluid Rhinorrhea; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Rhinitis | 2014 |
Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Recovery of Function; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Urinary Bladder; Urodynamics; Urological Agents | 2015 |
The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Bladder; Urodynamics | 2015 |
The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Autonomic Nervous System; Blood Glucose; Body Mass Index; Erectile Dysfunction; Humans; Lipids; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Risk Factors; Sulfonamides; Tamsulosin; Testosterone | 2014 |
Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Antihypertensive Agents; Humans; Hypertension; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quinazolines; Urological Agents | 2015 |
Authors' reply.
Topics: Antihypertensive Agents; Humans; Hypertension; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quinazolines; Urological Agents | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
[Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological | 2015 |
The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study.
Topics: Accidental Falls; Adrenergic alpha-1 Receptor Antagonists; Aged; Canada; Craniocerebral Trauma; Fractures, Bone; Humans; Hypotension; Indoles; Male; Outcome Assessment, Health Care; Prostate; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Risk Factors; Sulfonamides; Tamsulosin | 2015 |
Modified corneal incisions in intraoperative floppy iris syndrome (IFIS)-prone patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Cornea; Drug Combinations; Humans; Incidence; Intraoperative Complications; Iris Diseases; Male; Middle Aged; Phacoemulsification; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2016 |
Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.
Topics: Blotting, Western; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Male; Muscle Contraction; Muscle Tonus; Muscle, Smooth; Prostate; Prostatic Hyperplasia; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; src-Family Kinases; Stromal Cells | 2016 |
The effect of various alpha1-adrenergic receptor antagonists on pupillary dilation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Iris Diseases; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Ejaculation; Humans; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 2009 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin | 2010 |
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Combinations; Humans; Hypertension; Male; Middle Aged; Models, Biological; Polypharmacy; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; Endothelial Cells; Endothelium, Vascular; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography | 2011 |
Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Quinazolines; Thrombocytopenia | 2010 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Family Practice; Humans; Indoles; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2012 |
The effect of alpha antagonists on pupil dynamics: implications for the diagnosis of intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Case-Control Studies; Cataract Extraction; Diagnostic Techniques, Ophthalmological; Humans; Intraoperative Complications; Iris Diseases; Male; Muscle Hypotonia; Muscle, Smooth; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Tamsulosin | 2012 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Taiwan; Treatment Outcome | 2012 |
Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Finasteride; Glaucoma; Humans; Male; Middle Aged; Optic Neuropathy, Ischemic; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Vision Disorders | 2013 |
The efficacy of alfuzosin treatment in patients with prostatism.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Treatment Outcome; Urodynamics | 2001 |
Benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2003 |
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Animals; Erectile Dysfunction; Male; Muscle Relaxation; Penile Erection; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Rabbits; Sildenafil Citrate; Sulfones | 2003 |
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; Aza Compounds; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Approval; Electrocardiography; Fluoroquinolones; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Moxifloxacin; Phosphoric Diester Hydrolases; Piperazines; Prostatic Hyperplasia; Quinazolines; Quinolines; Risk Assessment; Sulfones; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2003 |
Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors; Urinary Bladder Neck Obstruction; Urodynamics | 2003 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urinary Retention | 2003 |
Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Contraindications; Drug Interactions; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
On call. My doctor gave me a prescription for Uroxatral to treat my enlarged prostate. I tried to look up this medicine in your Harvard Medical School Guide to Men's Health, but I couldn't find it. What can you tell me about Uroxatral?
Topics: Adrenergic beta-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Probability; Prostatic Hyperplasia; Quinazolines; Reference Values; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2005 |
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Decision Support Techniques; Drug Costs; Emergency Treatment; Follow-Up Studies; Humans; Male; Middle Aged; Monte Carlo Method; Prostatectomy; Prostatic Hyperplasia; Quinazolines; United Kingdom; Urinary Retention | 2005 |
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Topics: Adrenergic alpha-Antagonists; Delayed-Action Preparations; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urination Disorders | 2005 |
Effects of selective alpha-1-adrenergic receptor blockers on bladder weight.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Hypertrophy; Male; Middle Aged; Organ Size; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography; Urinary Bladder | 2006 |
Are all alpha-blockers created the same?
Topics: Adrenergic alpha-Antagonists; Adult; Clinical Trials as Topic; Dizziness; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2006 |
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines; Risk Factors; Urination Disorders | 2006 |
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Libido; Male; Middle Aged; Patient Satisfaction; Penile Erection; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Intraoperative floppy iris syndrome in a patient taking alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Aged, 80 and over; Cataract Extraction; Humans; Intraoperative Complications; Iris; Male; Prostatic Hyperplasia; Quinazolines; Syndrome | 2006 |
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Cross-Sectional Studies; France; Health Care Surveys; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Stents; Treatment Outcome; Urinary Catheterization; Urinary Retention | 2006 |
Toxic epidermal necrolysis caused by alfuzosin, an alpha1-adrenoceptor antagonist.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Diagnosis, Differential; Exanthema; Fever; Humans; Male; Prostatic Hyperplasia; Quinazolines; Skin Ulcer; Stevens-Johnson Syndrome | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2006 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Female; Humans; Incidence; Intraoperative Complications; Iris Diseases; Male; Naphthalenes; Piperazines; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2007 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; Prevalence; Prostatic Hyperplasia; Purines; Quality of Life; Quinazolines; Risk Factors; Sildenafil Citrate; Sulfones; Urination Disorders | 2007 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cataract Extraction; Doxazosin; Female; Humans; Hypertension; Incidence; Intraoperative Complications; Iris Diseases; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2007 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; Middle Aged; Organ Size; Predictive Value of Tests; Premedication; Prognosis; Prospective Studies; Prostate; Prostatic Hyperplasia; Quinazolines; Statistics as Topic; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urinary Retention; Urodynamics | 2007 |
Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Incidence; Intraoperative Complications; Iris Diseases; Male; Odds Ratio; Phacoemulsification; Postoperative Complications; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2007 |
Alfuzosin-induced acute liver injury.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Dysuria; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 2007 |
Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.
Topics: Drug Evaluation, Preclinical; Electrochemistry; Electrodes; Humans; Hydrogen-Ion Concentration; Male; Molecular Structure; Pharmaceutical Preparations; Potentiometry; Prostatic Hyperplasia; Quinazolines; Reference Values; Sensitivity and Specificity | 2007 |
Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Treatment Outcome | 2008 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturia; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2008 |
Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.
Topics: Binding Sites; Binding, Competitive; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha; Tritium | 1984 |
[Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Time Factors | 1994 |
[Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction; Urodynamics | 1995 |
[Alpha blockers, TUS-P and TUR-P in the treatment of benign prostatic hypertrophy. A comparison using multivariate statistical analysis].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Time Factors; Urodynamics | 1995 |
Effect of bunazosin, alpha 1-adrenoceptor blocker, on multidirectional contractile response and localization of bunazosin binding sites in human hypertrophied prostate.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Autoradiography; Binding Sites; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Norepinephrine; Prostate; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha-1 | 1995 |
Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1996 |
[Drugs for prostatic adenoma].
Topics: Adrenergic alpha-Antagonists; Drug Monitoring; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1995 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Humans; Longitudinal Studies; Male; Middle Aged; Perception; Prostatic Hyperplasia; Psychometrics; Quality of Life; Quinazolines; Sensitivity and Specificity; Sexual Behavior; Surveys and Questionnaires; Urination Disorders | 1997 |
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow.
Topics: Adrenergic alpha-Antagonists; Computer Simulation; Humans; Male; Models, Biological; Observer Variation; Prostatic Hyperplasia; Quinazolines; Reproducibility of Results; Rheology; Urination; Urodynamics; Urologic Diseases | 1998 |
[The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Time Factors | 1997 |
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Male; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 1998 |
Alfuzosin-associated dermatomyositis.
Topics: Adrenergic alpha-Antagonists; Aged; Dermatomyositis; Humans; Magnetic Resonance Imaging; Male; Muscle Weakness; Muscle, Skeletal; Pain; Prostatic Hyperplasia; Quinazolines | 1998 |
Tamsulosine: new preparation. Capsules: alphablocker.
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Dizziness; Double-Blind Method; Drug Interactions; Ejaculation; Enzyme Inhibitors; Europe; Finasteride; Humans; Hypotension, Orthostatic; Japan; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Treatment Outcome | 1998 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Recurrence; Sickness Impact Profile; Urinary Retention; Urodynamics | 2000 |
Bunazosin. Andante, Detantol, E 1015, E 643, EA 0643.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Area Under Curve; Clinical Trials as Topic; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines | 1999 |
[Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Retrospective Studies; Time Factors | 2000 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseases; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Morbidity; Netherlands; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Research Design; Risk Factors; Sulfonamides; Tamsulosin | 2001 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Doxazosin; Drug Design; Humans; Indicators and Reagents; Indoles; Isoindoles; L Cells; Male; Mice; Models, Molecular; Molecular Conformation; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Recombinant Proteins; Spleen; Structure-Activity Relationship; Vas Deferens | 2001 |
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Phytotherapy; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2001 |
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Risk Factors; Sulfonamides; Tamsulosin; Time Factors; Treatment Failure | 2002 |
Characterization of some novel alpha 1-adrenoceptor antagonists in human hyperplastic prostate.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Aorta; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Piperidines; Prostatic Hyperplasia; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Spleen; Vas Deferens | 2002 |
[Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Premedication; Preoperative Care; Prostatectomy; Prostatic Hyperplasia; Quinazolines | 1992 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha | 1992 |
Alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urodynamics | 1991 |
[3H]bunazosin, a novel selective radioligand of alpha 1 adrenoceptors in human prostates.
Topics: Adrenergic alpha-Antagonists; Cell Membrane; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha; Tritium | 1991 |
[Characterization and localization of alpha 1-adrenoceptors in human prostate--with special reference to the zonal difference in receptor distribution].
Topics: Autoradiography; Binding Sites; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha; Urinary Bladder Neoplasms | 1991 |
Alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1991 |